Federal Rescheduling of Medical Marijuana Could Bring Down Drug Prices in Missouri

A federal decision to reclassify medical marijuana could lead to lower prices for consumers in Missouri, according to legal experts and advocates monitoring the change.

The Department of Justice has reclassified medical marijuana, moving it from its previous classification alongside drugs like heroin and LSD to a lower schedule that allows for expanded research opportunities. The shift marks a significant change in how the federal government treats a substance that has been legally available for medical use in dozens of states for years.

Dan Veits, a lawyer for the Missouri branch of the National Organization for the Reform of Marijuana Laws, noted that the rescheduling could have practical effects beyond research access. Lower scheduling typically means fewer regulatory hurdles for producers and distributors, which can translate into reduced costs that may eventually be passed on to consumers.

In Missouri, where medical marijuana is already legal under state law, the federal reclassification could ease some of the banking and tax complications that have plagued the industry. Cannabis businesses have long struggled with limited access to traditional banking services due to the federal classification, driving up operational costs.

The move also signals a broader shift in federal drug policy that could pave the way for further reforms, though full descheduling — removing marijuana from the Controlled Substances Act entirely — remains a more distant prospect.

What This Means For You: If you are a medical marijuana patient in Missouri or any state with a medical cannabis program, federal rescheduling could eventually mean lower prices, more product options, and easier access to banking services for the businesses you rely on. While the full impact will take time to materialize, this is a meaningful step toward normalizing the medical cannabis industry.